Peter Campitiello

Peter Campitiello, East Brunswick Office Managing Partner, represents public and private companies in corporate, securities, and commercial matters, including financing, mergers and acquisitions, corporate governance, and regulatory issues. He provides proactive and business-focused solutions, leveraging his broad network of funding, marketing and support firms for the benefit of his clients.

Peter routinely serves as outside general counsel to companies in the life sciences, alternative energy, cannabis, and private equity industries at all stages of their business life-cycle, advising on the many complex legal issues affecting their businesses. He has represented numerous companies in going public transactions, from organization through initial offerings, financing, and securities listings.

Closed a $5 million PIPE for our client Iveda Solutions, Inc. (Nasdaq: IVDA)—which specializes in IoT platforms that offer service providers a turn-key cloud video surveillance system, smart sensors, and intelligent video search technology—with institutional investors of common stock, pre-funded warrants and warrants.

Helped digital advertising platform Interactive Offers, LLC, sell its business to Grove, Inc. (Nasdaq: GRVI) for $6.1 million in cash and stock.

Helped digital sports recruiting platform Signing Day Sports, Inc., close on the pre-IPO bridge round for $6.3 million in advance of their IPO on Nasdaq next quarter.

Represented BioHiTech Global, Inc. (Nasdaq: BHTG), a sustainable technology and services company, in a $20 million Common Stock Purchase Agreement with Keystone Capital Partners.

Handled the reverse merger of Biosecurity Technology, LLC, which provides business solutions designed to reduce the risk of transmission of infectious diseases, into Axelerex Corp. (OTC: AEXL), and the simultaneous private placement of its common stock.

Assisted Chondrial Therapeutics, Inc., in entering into a definitive merger agreement with Zafgen, Inc., under which Chondrial will acquire Zafgen in a reverse merger wherein the stockholders of Chondrial will become the majority owners of Zafgen’s outstanding common stock. Stockholders of Chondrial will receive shares of newly issued Zafgen common stock equal to approximately 60% of the company following the merger.

Represented NanoViricides, Inc. in an underwritten offering of $11.5 million.

Represented BioHiTech Global, Inc. in an underwritten offering of $9.5 million.

Represented NanoViricides, Inc. in a market offering of $50 million.

Represented NanoViricides, Inc. in a public offering of $10.2 million.

Represented NanoViricides, Inc. in an underwritten offering of $8.625 million.

Represented BioHiTech Global, Inc. in a public offering of $3.15 million.